MX2013002556A - Polipeptido de fusion de dedo de serpina. - Google Patents

Polipeptido de fusion de dedo de serpina.

Info

Publication number
MX2013002556A
MX2013002556A MX2013002556A MX2013002556A MX2013002556A MX 2013002556 A MX2013002556 A MX 2013002556A MX 2013002556 A MX2013002556 A MX 2013002556A MX 2013002556 A MX2013002556 A MX 2013002556A MX 2013002556 A MX2013002556 A MX 2013002556A
Authority
MX
Mexico
Prior art keywords
serpin
polypeptide
fusion polypeptide
finger
biologically active
Prior art date
Application number
MX2013002556A
Other languages
English (en)
Inventor
Erhard Kopetzki
Richard Engh
Tilman Schlothauer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013002556A publication Critical patent/MX2013002556A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención comprende un polipéptido de fusión que comprende un polipéptido de dedo de serpina conjugado a un polipéptido biológicamente activo opcionalmente vía un polipéptido enlazante peptídico. Otro aspecto es un complejo de proteína de un polipéptido de fusión de dedo de serpina y una serpina, en donde el polipéptido de fusión se incorpora en la serpina en la parte media de la lámina beta A como cadena 4a. Un aspecto de la presente invención también es la preparación in vitro del complejo de proteína. El polipéptido de dedo de serpina se dirige y se fija al polipéptido biológicamente activo con alta afinidad y orientación espacial funcional.
MX2013002556A 2010-09-14 2011-09-13 Polipeptido de fusion de dedo de serpina. MX2013002556A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10176617 2010-09-14
PCT/EP2011/065884 WO2012035034A1 (en) 2010-09-14 2011-09-13 Serpin-finger fusion polypeptide

Publications (1)

Publication Number Publication Date
MX2013002556A true MX2013002556A (es) 2013-05-28

Family

ID=44653317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002556A MX2013002556A (es) 2010-09-14 2011-09-13 Polipeptido de fusion de dedo de serpina.

Country Status (11)

Country Link
US (1) US9403896B2 (es)
EP (1) EP2616487B1 (es)
JP (1) JP5757639B2 (es)
KR (1) KR20130045385A (es)
CN (1) CN103108884A (es)
BR (1) BR112013002292A2 (es)
CA (1) CA2808675A1 (es)
ES (1) ES2535704T3 (es)
MX (1) MX2013002556A (es)
RU (1) RU2013113723A (es)
WO (1) WO2012035034A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160089390A (ko) * 2013-12-10 2016-07-27 에프. 호프만-라 로슈 아게 다중-하부단위 구조에 대한 약학적 활성 개체의 표적화 전달을 위한 다중-하부단위 구조의 하부단위의 결합 도메인의 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE68904264T2 (de) 1988-08-24 1993-05-27 Akzo Nv Fragmente und fraktionen von heparin mit wirkung gegen hiv.
DE69326069T2 (de) 1992-07-20 2000-03-23 Univ Durham Zusammensetzungen die die hiv replikation inhibieren
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
KR100571215B1 (ko) 1995-06-07 2006-10-24 트라이머리스 인코퍼레이티드 복합적인치료요법을이용한hiv와다른바이러스감염의치료
WO1997024453A1 (en) 1995-12-28 1997-07-10 Chiron Corporation Receptor specific chimeric viral surface polypeptides for viral and particle incorporation and internalization in target cells
EP0927764B1 (de) * 1997-12-03 2004-05-26 Boehringer Mannheim Gmbh Chimäre Serinproteasen
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6291245B1 (en) 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
EP0972838B1 (en) 1998-07-15 2004-09-15 Roche Diagnostics GmbH Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
AU3719100A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
EP1264840B1 (en) 1999-05-17 2009-09-23 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
CA2430973A1 (en) * 2000-12-18 2002-06-27 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
ES2296914T3 (es) * 2001-01-26 2008-05-01 The General Hospital Corporation Farmacos de serpina para el tratamiento de la infeccion por vih y metodo de uso de los mismos.
WO2002063017A2 (en) 2001-02-05 2002-08-15 Trigen Limited Integrin-binding chimeras
EP1471928A1 (en) * 2002-02-07 2004-11-03 Delta Biotechnology Limited Hiv inhibiting proteins
CA2443365C (en) 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
CA2537273A1 (en) * 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
WO2005067960A1 (en) 2004-01-07 2005-07-28 Trimeris, Inc. HIV gp41 HR2-DERIVED SYNTHETIC PEPTIDES, AND THEIR USE IN THERAPY TO INHIBIT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS
CL2008000707A1 (es) * 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
CL2008002092A1 (es) * 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.

Also Published As

Publication number Publication date
RU2013113723A (ru) 2014-10-20
CA2808675A1 (en) 2012-03-22
BR112013002292A2 (pt) 2016-06-14
JP2013542186A (ja) 2013-11-21
KR20130045385A (ko) 2013-05-03
US9403896B2 (en) 2016-08-02
US20140045742A1 (en) 2014-02-13
CN103108884A (zh) 2013-05-15
EP2616487B1 (en) 2015-03-25
EP2616487A1 (en) 2013-07-24
ES2535704T3 (es) 2015-05-14
JP5757639B2 (ja) 2015-07-29
WO2012035034A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
AU2018201441B2 (en) Xten conjugate compositions and methods of making same
NZ612312A (en) Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota
NZ600732A (en) Oxyntomodulin peptide analogue
AU2017204797B2 (en) Antibodies with modified isoelectric points
MX2023010178A (es) Conjugados de anticuerpo farmaco anti-cd70.
NZ602522A (en) Biosynthetic proline/alanine random coil polypeptides and their uses
NZ603813A (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
WO2009105671A3 (en) Methods and compositions related to peptides and proteins with c-terminal elements
MY160552A (en) Low protein infant formula with increased essential amino acids
NZ607069A (en) Modified relaxin polypeptides and their uses
WO2015054590A3 (en) NON-NATURAL AMINO ACID tRNA SYNTHETASES FOR PYRIDYL TETRAZINE
NZ600731A (en) Oxyntomodulin peptide analogue
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MX344219B (es) Productos farmaceuticos peptidicos mejorados para resistencia a insulina.
EP4286400A3 (en) Improved peptide pharmaceuticals
SG10201809286XA (en) Biologically active peptides
EP2651964A4 (en) NETWORKED PEPTIDES AND PROTEINS, METHOD FOR THEIR PREPARATION AND USES THEREOF
NZ623294A (en) Stabilized alpha-galactosidase and uses thereof
WO2009064366A3 (en) Methods and compositions for protein labeling using lipoic acid ligases
GB2517354A (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
WO2013014677A8 (en) Matrix compositions for controlled release of peptide and polypeptide molecules
GB201110815D0 (en) Incorporation of subtituted lysines into polypeptides
EP2536287A4 (en) SPECIFIC SITE SIZE OF PROTEINS USING CHEMICAL MODIFICATION TO PROMOTE PROTEIN CONJUGATE FORMATION, PROTEIN DIMER FORMATION, AND AGRAFTED PEPTIDES
GB201008720D0 (en) RxLR-leader peptides and protein translocation
WO2009120895A3 (en) Recombinant bacteriophages useful for tissue engineering

Legal Events

Date Code Title Description
FA Abandonment or withdrawal